RUSPRice Undergraduate Scholars Program (Rice University; Houston, TX)
RUSPReserve Unit Support Program (Canada)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Secretary of Health and Human Services recommended that critical congenital heart defects (CCHD) be added to the Recommended Uniform Screening Panel (RUSP) for newborns.
To assess the differences between state birth defect surveillance programs, in October 2010, after the SACHDNC recommendation to add screening for CCHD to RUSP, CDC collaborated with the National Birth Defects Prevention Network, a national network of state and population-based programs for birth defects surveillance and research, to create and distribute an electronic survey to birth defects surveillance program primary contacts (6) in all 50 states, the District of Columbia, and Puerto Rico.
Critical congenital heart disease (CCHD) is the most recently added condition to the RUSP. Currently, only two states (New Jersey and Indiana) screen every baby born for CCHD, but others have passed legislation or started working groups indicating that screening could begin soon.
Despite the increasing availability of treatment options which have been shown to lead to better outcomes when initiated early in life; only 2 diseases (Pompe disease and MPS-I) have recently been added to the RUSP. However, based on the results obtained from several pilot programs implemented in the US, Taiwan and other countries (50, 51), more conditions will probably be added in the future.
Their newborn screening initiative seeks to provide legislative support to states so that they begin screening for recommended conditions within a set time frame and create resources for families and organizations to help add new diseases to the RUSP and state panels.
Moreover, I believe we should initiate NBS only for conditions that have been recommended by the SACHDNC, which at this time has approved only 2 LSDs, Pompe disease and Hurler syndrome (MPS-IH), for inclusion in the RUSP. I am not fundamentally opposed to screening for other LSDs that have US Food and Drug Administration (FDA)-approved treatments, but it seems to me that it would be prudent to first conduct pilot prospective studies for evidence-based review by the SACHDNC.
That changed in 2010 when the United States Secretary's Advisory Committee for Heritable Disorders of Newborns and Children (SACHDNC) voted unanimously to add screening for severe combined immunodeficiency (SCID) and other causes of T cell lymphopenia to the recommended uniform screening panel (RUSP) for newborns.
This report received a lot of criticism, but the Recommend Uniform Screening Panel (RUSP) was endorsed by the Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC), a federal newborn screening advisory committee.
To the University of Sao Paulo for the grant in Initiation in the Scientific Method (Iniciacao-Cientifica) for Tais de Fatima Borges Camargo (RUSP Institutional Scholarship) during the execution of the study.
Department of Health and Human Services (HHS) Secretary endorsed the recommendation that critical congenital heart defects be added to the Recommended Uniform Screening Panel (RUSP) for all newborns (4).